• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility

    6/9/25 10:00:00 AM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email

    Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1

    With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone-conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient.2 

    The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee.

    "We're entering an exciting era in knee replacement, driven by the momentum of personalized medicine and an influx of innovative approaches," said Dr. Steve McDonald, Chief of Orthopaedics and Chief of Surgery, at London Health Sciences Centre in London, Ontario. "With US registry data now showing that one in three total knees utilize a medial stabilized design, it's clear that surgeons are increasingly turning to solutions that offer more natural kinematics and higher patient satisfaction. The LEGION Medial Stabilized TKS stands out in this space - offering a powerful combination of medial stabilized kinematics, advanced porous fixation, integration with technologies like the CORI◊ Surgical System, and a strong clinical legacy. It's an ideal solution for surgeons looking to align with the principles of personalized care."



    The LEGION TKS has demonstrated more than 20 years of clinical success,3 with the new medial stabilized insert adding a modern design to align with rapidly growing market trends. The LEGION Medial Stabilized TKS is the latest addition to the LEGION portfolio supporting both the LEGION CONCELOC◊ Cementless and LEGION Cemented Total Knee Systems.

    "LEGION Medial Stabilized TKS is the latest evolution of the trusted LEGION brand - a platform backed by over 20 years of performance and innovation," said Craig Gaffin, President, Global Orthopaedics for Smith+Nephew. "As market demand for porous and kinematically advanced knee solutions continues to grow, we believe this addition will elevate the LEGION portfolio even further, enabling us to better meet the evolving needs of patients and surgeons alike."

    The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026. To hear more from Dr. MacDonald and Craig Gaffin, please visit here.

     - ends -

     

    Enquiries

    Media 
    David Snyder+1 978-749-1440
    Smith+Nephew



     



     
     

    References

    1. American Joint Replacement Registry (AJRR) 2024 Annual Report.
    2. https://pmc.ncbi.nlm.nih.gov/articles/PMC12089135/#s4
    3. Victor J, Ghijselings S, Tajdar F, et al. Total knee arthroplasty at 15-17 years: does implant design affect outcome? Int Orthop. 2014;38(2):235-241.

     

    About Smith+Nephew

    Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

    Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 ((LSE:SN, NYSE:SNN). The terms ‘Group' and ‘Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

    For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

     

    Forward-looking Statements

    This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

    ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.



    Primary Logo

    Get the next $SNN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    6/5/2024Neutral → Buy
    UBS
    11/28/2023Underweight → Equal Weight
    Barclays
    11/3/2023Neutral → Overweight
    JP Morgan
    More analyst ratings

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by Berenberg

      Berenberg downgraded Smith & Nephew from Buy to Hold

      11/6/24 6:23:06 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    SEC Filings

    See more
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      7/1/25 11:55:37 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      6/13/25 11:12:35 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      6/6/25 1:20:14 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

      3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

      2/12/21 6:00:30 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of ‘Life Unlimited' - making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint re

      6/29/25 7:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings 'next-level nailing' to trauma surgeons repairing tibial fractures

      The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-ce

      6/24/25 10:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

      6/23/25 8:00:00 AM ET
      $LAZ
      $SNN
      Investment Managers
      Finance
      Industrial Specialties
      Health Care

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

      2/3/21 1:13:21 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

      6/23/25 8:00:00 AM ET
      $LAZ
      $SNN
      Investment Managers
      Finance
      Industrial Specialties
      Health Care
    • Cadence Welcomes Bob White to Board of Directors

      STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

      9/12/24 10:57:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Financials

    Live finance-specific insights

    See more
    • Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

      New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

      3/3/25 8:20:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

      New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

      8/29/22 3:20:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

      Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an

      6/1/22 2:30:00 AM ET
      $SNN
      Industrial Specialties
      Health Care